Cardio Diagnostics Holdings has entered into an at-market offering agreement with Craig-Hallum Capital Group LLC to sell up to $9.48M of common stock. The sales will be made through ordinary brokers' transactions at market prices on Nasdaq or other trading venues, with Craig-Hallum receiving a 2.5% commission.The offering provides flexibility in timing and amount of shares sold, with no minimum offering amount required. The net proceeds will depend on the number of shares sold and market prices. As of December 11, 2024, the company's public float was valued at $73.6M, with 48.42M shares held by non-affiliates at $1.52 per share.The company is subject to Form S-3 offering limitations and has sold $15.06M of securities in the past 12 months. Under General Instruction I.B.6, Cardio cannot sell securities exceeding one-third of its public float in any 12-month period while its float remains below $75M.

Cardio Diagnostics Holdings has entered into an at-market offering agreement with Craig-Hallum Capital Group LLC to sell up to $9.48M of common stock. The sales will be made through ordinary brokers' transactions at market prices on Nasdaq or other trading venues, with Craig-Hallum receiving a 2.5% commission.The offering provides flexibility in timing and amount of shares sold, with no minimum offering amount required. The net proceeds will depend on the number of shares sold and market prices. As of December 11, 2024, the company's public float was valued at $73.6M, with 48.42M shares held by non-affiliates at $1.52 per share.The company is subject to Form S-3 offering limitations and has sold $15.06M of securities in the past 12 months. Under General Instruction I.B.6, Cardio cannot sell securities exceeding one-third of its public float in any 12-month period while its float remains below $75M.